Evotec OAI (Germany) (EVTG.F) To Present At The Piper Jaffray London Health Care Conference  
6/20/2006 2:23:28 PM

HAMBURG, Germany and OXFORD, England, June 20 /PRNewswire-FirstCall/ -- Evotec today announced that Joern Aldag, President & CEO, and Dr John Kemp, EVP Research & Development, will present at the Piper Jaffray Health Care Conference at 3.40 p.m. GMT on Thursday, 22 June 2006, at The Brewery in London.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through contract research partnerships, the Company is providing highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the central nervous system (CNS). Evotec has three Phase I clinical programmes: EVT 201, a GABAA modulator for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and EVT 301, a selective and reversible inhibitor of MAO-B for the treatment of Alzheimer's disease.

In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.

In 2005, Evotec has generated sales of EUR 80 million with approximately 600 people located in Hamburg, Germany and near Oxford and in Glasgow, UK. Contact: Evotec AG Anne Hennecke Director, Investor Relations & Corporate Communications Phone: +49-(0)40-560-81-286

Evotec AG

CONTACT: Contact: Evotec AG, Anne Hennecke, Director, Investor Relations &Corporate Communications, Phone: +49-(0)40-560-81-286,